Insider Selling: Arcus Biosciences (NYSE:RCUS) President Sells 44,950 Shares of Stock

Arcus Biosciences, Inc. (NYSE:RCUS) President Juan Jaen sold 44,950 shares of the company’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $20.31, for a total value of $912,934.50. Following the completion of the transaction, the president directly owned 1,042,110 shares of the company’s stock, valued at approximately $21,165,254.10. The trade was a 4.14% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Arcus Biosciences Trading Up 0.3%

Shares of NYSE:RCUS traded up $0.06 during midday trading on Wednesday, hitting $20.25. 1,141,207 shares of the stock were exchanged, compared to its average volume of 1,097,460. The business’s 50-day moving average price is $16.08 and its 200 day moving average price is $11.75. Arcus Biosciences, Inc. has a 12 month low of $6.50 and a 12 month high of $22.11. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.65 and a current ratio of 3.65. The stock has a market capitalization of $2.19 billion, a price-to-earnings ratio of -5.89 and a beta of 0.90.

Arcus Biosciences (NYSE:RCUS) last posted its earnings results on Tuesday, October 28th. The company reported ($1.27) EPS for the quarter, topping the consensus estimate of ($1.33) by $0.06. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The business had revenue of $26.00 million for the quarter, compared to the consensus estimate of $19.89 million. During the same period last year, the company earned ($1.00) EPS. The firm’s revenue was down 45.8% compared to the same quarter last year. Analysts predict that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current year.

Institutional Investors Weigh In On Arcus Biosciences

A number of large investors have recently bought and sold shares of the stock. GAMMA Investing LLC boosted its position in shares of Arcus Biosciences by 59.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock worth $37,000 after purchasing an additional 1,021 shares in the last quarter. SBI Securities Co. Ltd. raised its stake in Arcus Biosciences by 13,547.6% during the 3rd quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock worth $39,000 after buying an additional 2,845 shares during the period. CWM LLC raised its stake in Arcus Biosciences by 233.6% during the 2nd quarter. CWM LLC now owns 5,441 shares of the company’s stock worth $44,000 after buying an additional 3,810 shares during the period. Ameritas Investment Partners Inc. boosted its holdings in Arcus Biosciences by 34.3% in the second quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company’s stock worth $57,000 after acquiring an additional 1,796 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its stake in Arcus Biosciences by 440.3% in the second quarter. PNC Financial Services Group Inc. now owns 7,597 shares of the company’s stock valued at $62,000 after acquiring an additional 6,191 shares during the period. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on RCUS. Wells Fargo & Company boosted their price objective on shares of Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a research note on Monday, October 20th. Wall Street Zen lowered Arcus Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, November 1st. Citigroup raised their price objective on Arcus Biosciences from $54.00 to $56.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Wedbush set a $35.00 price objective on Arcus Biosciences and gave the stock an “outperform” rating in a research note on Wednesday, October 29th. Finally, The Goldman Sachs Group increased their target price on shares of Arcus Biosciences from $14.00 to $16.00 and gave the company a “neutral” rating in a research report on Thursday, October 30th. Seven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Arcus Biosciences currently has an average rating of “Moderate Buy” and an average target price of $28.44.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.